Safety and Immunogenicity of Modified Vaccinia Ankara-Bavarian Nordic Smallpox Vaccine in Vaccinia-Naive and Experienced Human Immunodeficiency Virus-Infected Individuals: An Open-Label, Controlled Clinical Phase II Trial

BACKGROUND: First- and second-generation smallpox vaccines are contraindicated in individuals infected with human immunodeficiency virus (HIV). A new smallpox vaccine is needed to protect this population in the context of biodefense preparedness. The focus of this study was to compare the safety and...

Descripción completa

Detalles Bibliográficos
Autores principales: Overton, Edgar Turner, Stapleton, Jack, Frank, Ian, Hassler, Shawn, Goepfert, Paul A, Barker, David, Wagner, Eva, von Krempelhuber, Alfred, Virgin, Garth, Weigl, Josef, Meyer, Thomas Peter, Müller, Jutta, Bädeker, Nicole, Grünert, Robert, Young, Philip, Rösch, Siegfried, Maclennan, Jane, Arndtz-Wiedemann, Nathaly, Chaplin, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2015
Materias:
Major Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4567089/
https://www.ncbi.nlm.nih.gov/pubmed/26380340
http://dx.doi.org/10.1093/ofid/ofv040

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4567089/
https://www.ncbi.nlm.nih.gov/pubmed/26380340
http://dx.doi.org/10.1093/ofid/ofv040

Ejemplares similares